The GLP-1/GIP dual-receptor agonist tirzepatide led to at least 15% loss of total body fat in premenopausal, perimenopausal, and postmenopausal women, but postmenopausal women taking menopausal ...

Much like the Cold War space race, the world's pharmaceutical giants are currently scrambling to produce the best weight-loss drug. They all want to be the first to explore the nooks and crannies of ...

Feb. 5, 2026 -- In 2025, the U.S. FDA removed the “black box” warnings from menopausal hormone therapy products – but what does that actually mean for patients? For decades, many women have navigated ...

DMPA denotes depot medroxyprogesterone acetate, GAHT gender-affirming hormone therapy, GnRH gonadotropin-releasing hormone, HRT hormone-replacement therapy, and MPA medroxyprogesterone acetate.

Insulin resistance is one area under investigation. If you have been diagnosed with the condition, here’s how GLP-1s may help ...

GLP-1 weight loss drugs have quickly moved from medical journals to household conversations, reshaping how Americans think about obesity, diabetes and weight loss. Headlines often describe them as ...

Hormone therapy is the gold standard for treating VMS, but requires careful patient selection and shared decision-making. Timing, dose, and formulation of hormone therapy are crucial for safety and ...